3 Moonshot Stocks With the Potential to Turn $10K Into $100K

  • Stock investing isn’t without risks but these three stocks have a solid runway.
  • Pfizer (PFE): Pfizer has a strong drug pipeline but it will need a few years to improve the balance sheet after the dip in Covid vaccine sales. 
  • SoFi Technologies (SOFI): SoFi’s second-quarter results could be impressive and give the stock a much-needed push. 
  • Disney (DIS): Disney’s Experiences segment is the engine that will keep the business running. 
high-growth potential stocks - 3 Moonshot Stocks With the Potential to Turn $10K Into $100K

Source: shutterstock.com/Pasuwan

For a long-term, low-risk investor like me, picking stocks can be tough. I want to ensure I see capital growth but I am scared to take big risks. However, there are also times when I see penny stocks doubling or moonshot stocks soaring 50% in six months and this is when I think I should lean a little on riskier stocks. If you want big gains, you’ve got to be ready to take risks and pick high-growth potential stocks.

Warren Buffett didn’t reach the top without taking any risks. I’ve identified three moonshot stocks that come with a risk but have a huge runway.

While they are well-known companies, they are taking several risks to turn around their businesses and this is what makes them moonshot stocks. One company is trying to move away from its personal loan business, another is hoping to turn its streaming business into a profit-making unit and the third one is working on a new weight loss drug. If all goes well, these stocks will hit the sky. If you’re here for high-risk, high-reward, here are three stocks to consider. 

High-Growth Potential Stock No. 1: Pfizer (PFE)

blue Pfizer logo on the windows of a corporate building PFR stock
Source: photobyphm / Shutterstock.com

Pfizer (NYSE:PFE) has a long record of blockbuster drugs. From Lipitor and Viagra to Xanax and more recently the Covid vaccine, the pharmaceutical giant has produced some of the most successful billion-dollar drugs ever.

The biggest concern today, though, is declining revenue from falling vaccine sales. It will take some time for Pfizer to recover from the dip but the stock looks like a solid long-term bet. 

It hit a high of $58 in December 2021 and has been on a downward spiral since. PFE stock is exchanging hands for $28 today and has dropped 2.7% year-to-date (YTD). Shares have been trading in the range of $25 to $29 since the start of the year. However, investors must look beyond the vaccine and consider its drug pipeline when considering whether to invest in the stock.

Pfizer recently announced it will proceed with clinical trials on a once-daily version of the weight-loss pill danuglipron based on “encouraging” data. It will begin to conduct early-stage trials in the second half of 2024. The pharmaceutical is trying to grab a slice of the massive weight-loss drug industry. While this is a risk management is taking, if the drug passes the necessary trials, it could work wonders for the business. That makes it an ideal moonshot pick.

Pfizer also has a dividend yield of 5.86% which is one of the best in the industry and if all goes well, this stock could double your money. However, things will get worse before they get better. Management is cutting costs but the transition will take time. It aims to add $25 billion in revenue by 2030 through acquisitions but until then, the balance sheet might not look its best. 

SoFi Technologies (SOFI)

SoFi logo at their headquarters location. SOFI stock.
Source: Michael Vi / Shutterstock

Fintech stock SoFi Technologies (NASDAQ:SOFI) had a lot going for it but the stock didn’t budge. Trading at $6 today, it is down 27% YTD and hasn’t been able to hit double digits since last March. Despite reporting stellar fundamentals, user growth and a profitable quarter, SoFi isn’t where it should be. 

Investors are worried that the company is heavily dependent on personal loans and this could harm profitability. Since personal loans are unsecured, the business is riskier. The lending segment in the first-quarter saw a 22% YOY increase with the personal loan segment growing 11% YOY. 82% of the lending segment revenue came from net interest income, reflecting the company’s heavy dependability on the segment. An interest rate cut could have an impact on this segment and the company could see a revenue dip. It will be interesting to see how it navigates through this situation.

On the other hand, its membership grew 44% year-over-year and net revenue surged 26% in the first quarter. These numbers show that SoFi has a lot to offer and it managed to report two straight quarters of profitability after net losses. SOFI is one of the high-growth potential stocks to invest in.

If you can take the risk now and buy SoFi stock below $10, its massive upside could generate abundant returns. The stock is trading at a reasonable valuation, making it a buy now. 

Disney (DIS)

Disney logo on a store front. DIS stock.
Source: chrisdorney / Shutterstock

I consider Disney (NYSE:DIS) as a moonshot stock because the company has established itself in the streaming industry but has been unsuccessful in its attempt to turn the business around over the past few years. The pandemic had a devastating impact on Disney but the streaming catalogue helped it remain afloat. Its profits are lower than the pre-pandemic levels and after growing slightly in 2022, they dipped in 2023.

However, Disney’s theme parks continue to bring revenue while the streaming segment is losing money. The company suffered last year and reported losses but it made a minimal profit in May. Disney’s streaming business has more than 200 million subscribers and it has not been able to generate a profit until last quarter.

Yet management is working to turn the streaming segment profitable. It signed a deal valued at $8.5 billion with India’s Reliance Industries for both companies to combine their television assets and streaming services in India. The joint venture will target 750 million viewers in the country.

One solid reason to bet on this stock is the theme parks. I believe theme parks will save Disney and could give it a stronger position. The company is building its fifth theme park in Orlando. To make the most of the popularity of theme parks, the company has announced a $60 billion investment in the Experiences segment over the next decade. 

Trading at $97, the stock is up 7% YTD and 13% in the past 12 months. 

On the date of publication, Vandita Jadeja did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Vandita Jadeja is a CPA and a freelance financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis.


Article printed from InvestorPlace Media, https://investorplace.com/2024/07/3-moonshot-stocks-with-the-potential-to-turn-10k-into-1-million/.

©2024 InvestorPlace Media, LLC